Fate Therapeutics, Inc. Board of Directors

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Dr. Jerome Bressi Ph.D.

Dr. Jerome Bressi Ph.D.

Chief Regulatory & Quality Officer

Ms. Cindy R. Tahl J.D.

Ms. Cindy R. Tahl J.D.

Chief Legal & Compliance Officer and Corporate Secretary

Mr. Andrew Henry

Mr. Andrew Henry

Senior Vice President of Clinical Operations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.